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Purpose of this study was to evaluate the association of the spatial heterogeneity (aspheri-
city, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive
metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphologi-
cal treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we cor-
related ASP derived form a pre-therapeutic OctreoScan (ASP[In]) and an intra-therapeutic
[177Lu]-SPECT/CT (ASP[Lu]).
Materials and methods
Data from first therapy cycle [177Lu-DOTA0-Tyr3]octreotate ([177Lu]-DOTATATE)-PRRT was
retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46–88] years). The
evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions
[RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of
SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test
and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs.
NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic
ASP was determined with Spearman’s rank correlation coefficient (ρ) and Bland-Altman plots.
Results
A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were
analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT
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(PD, median: 11.3, IQR: 8.5–15.5; SD, median: 3.4, IQR: 2.1–4.5; PR, median 1.7, IQR:
0.9–2.8; CR, median: 0.5, IQR: 0.0–1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed
a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001)
and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sen-
sitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic
ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP[In] and
ASP[Lu] was -0.04 (95% Limits of Agreement, -6.1–6.0).
Conclusion
Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for
therapy monitoring.
Introduction
Neuroendocrine neoplasms of the gastroenteropancreatic system (GEP-NEN) represents a
rare and heterogeneous tumor entity. However, the incidence of GEP-NEN increased recently,
mainly due to improved functional imaging and device-specific sensitivity[1]. Beyond com-
monly “cold” agents, such as somatostatin analogs, as a first-line antiproliferative drug, peptide
receptor radionuclide therapy (PRRT) with [177Lu-DOTA0-Tyr3]octreotate ([177Lu]DOTA-
TATE) has emerged as a highly effective treatment in metastatic well-differentiated GEP-NEN
of low and intermediate grade G1 and G2. [2, 3]. Several retrospective studies could also show
the superiority of [177Lu]DOTATATE-PRRT in advanced inoperable GEP-NEN compared to
other treatment modalities[4–6]. The recently published results of the first prospective ran-
domized study in patients with progressive metastatic midgut NEN, NETTER-1, found a rate
of 65.2% progression-free survival at month 20 after PRRT. In particular, the overall survival
(OS) has not yet been reached in the study cohort [7]. In contrast, the current published
ENETS guidelines recommend the use of PRRT in intestinal (midgut) NEN with distance and/
or loco regional metastases as a second- to third-line therapy after progression under somato-
statin-analogues (SSA) irrespective of the abovementioned NETTER-1 results. According to
guidelines in pancreatic NEN with advanced locoregional disease PRRT should be even used
as a third line therapy after failure of SSA, everolimus and/ or cytotoxic chemotherapy [8].
Meanwhile, application of PRRT can be only repeated to a limited extent, imposed by criti-
cal dose exposure in different organs at risk, e.g. in bone marrow (<2Gy) [9, 10] in 70% of
patients after treatment with [177Lu]DOTATATE and in kidney (<40 Gy) [11]. Histological
diversities in metastatic SSR-expression are common findings, and may deliver objective pre-
diction of therapy efficacy [12, 13]. However, not all patients benefit from PRRT. Therefore,
better stratification criteria are highly desirable to identify patients with high probability for
tumor response.
Until now, diagnosis and staging of NEN are merely based on analysis of tumor spread and
morphology in imaging, irrespective of SSR expression and density.
Promising results have been published considering features from the non-invasive SSR-
imaging that can be used separately or in combination to characterize more accurately biologi-
cal behavior of NEN, thus leading to a better understanding of tumor/therapy response. The
Krenning score, a well-established qualitative measure [3, 14], the metastases to liver ratio (M/
L ratio), a first scanner-independent quantitative surrogate in [68Ga-DOTA0-Phe1-Tyr3]
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octreotide (DOTATOC)-positron emission tomography (PET) combined with computed
tomography (CT) [15], as well as the intratumoral SSR-heterogeneity in [68Ga]DOTATATE--
PET/CT [16] represent the most common methodologies in prediction of response in PRRT.
The assessment of asphericity (ASP), characterizing lesion’s spatial SSR-heterogeneity e.g. by
[111In-DTPA0]octreotide ([111In]octreotide, OctreoScan) scintigraphy [13], demonstrated an
further promising parameter to predict response in PRRT planning [17]. Whereas, translation
and verification of this novel image based methodology to intra-therapeutic workflow is
missing.
The aim of the present study was to evaluate the predictive capability of tumoral SSR-recep-
tor heterogeneity based on intra-therapeutic imaging with [177Lu]DOTATATE. Secondly, we




In this monocentric setting, data of all consecutive patients (n = 33; f, n = 13; m = 20; median
age 72± 9.2 years, range, 46 to 88 years) treated by PRRT using [177Lu]DOTATATE were ret-
rospectively included in the period from June 2011 to September 2015. The patients fulfilled
the following inclusion criteria: (1) intra-therapeutic SPECT/CT (24 hours p.i.), (2) metastases
could be clearly delineated on SPECT imaging (33/37 patients; 89%), (3) GEP-NEN was histo-
logically proven, (4) patients underwent 2–4 cycles PRRT, (5) radiological follow up at least 12
months was available (33/41 patients; 80,5%). The assessment of tumor SSR-positivity was
determined by [111In]octreotide SPECT/CT or [68Ga]DOTATOC-PET/CT prior to therapy.
Further analysis was performed in a subset of twenty patients (f, n = 14; m = 6; median age 72±
7.4 years, range, 54 to 87 years) for a lesion-based correlation of ASP from pre-therapeutic
[111In]octreotide SPECT/CT with intra-therapeutic SPECT/CT.
All patients provided written informed consent on the evaluation of their data, and
approval from the institutional ethics committee of the Otto-von-Guericke-University (refer-
ence ID: RAD279; vote, 07/16) was obtained.
177Lutetium—Peptide receptor radionuclide therapy (PRRT)
All patients underwent PRRT in concordance to the Rotterdam protocol and The joint IAEA,
EANM and SNMMI practical guidance [18] as recently described [13]. In brief, patients
obtained a 177Lutetium-labelled (T1/2 = 6.7d) synthetic somatostatin analogue, [DOTA
0-Tyr3]
octreotate. The patients were treated by two to four cycles (median, 3.3; IQR 3–4; range 2–4)
of radionuclide therapy with a median administered activity of 200 mCi (7.4 GBq) [177Lu]
DOTATATE per cycle. Follow up including both morphological contrast-enhanced CT
(CE-CT) and functional imaging [111In]-OctreoScan, n = 12/33, 36%, or alternatively [68Ga]
DOTATOC-PET/CT, n = 15/33, 64%, was obtained after the second and fourth cycle and 4
and 12 months, respectively. If interim staging indicated progressive disease, no further cycle
of PRRT was administered [13].
SPECT/CT imaging
Intra-therapeutic imaging was performed with a dual head SPECT/CT (Discovery NM/
CT670, GE, Haifa, Israel) according to standard protocols. Planar imaging and SPECT with
low-dose CT (X-ray tube current = 40 mAs) of thorax and abdomen for morphological corre-
lation was carried out 24 hours p.i.. SPECT data were reconstructed by iterative algorithms
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with CT-based correction for attenuation as previously described [13]. Imaging data was eval-
uated with a dedicated workstation (Xeleris-Workstation, GE Healthcare, Waukesha, USA) at
standard clinical settings. Diagnostic CE-CT as well as contrast enhanced MRI of the liver was
performed according to a standard protocol, published elsewhere [13, 19].
Image analysis
Intra-therapeutic SPECT data sets were evaluated regarding SSR-heterogeneity in accumula-
tion pattern as previously described [13]. In brief, SPECT data measured 24h p.i. at the first
cycle [177Lu]-DOTATATE-PRRT was analyzed by a dedicated software (ROVER version
2.1.20, ABX, Radeberg, Germany). The functional tumor volume, a measure of the SSR uptake
of tumor tissue, was delineated by a semi-automatic algorithm based on adaptive threshold
taking the local background into account [20, 21]. For the resulting volumes of interest (VOI)










where S and V are the mean surface and volume of the lesions’ functional active part, respec-
tively. The ASP described the deviation of an activity accumulation from spherical geometry.
A small ASP (Range 1–5%) represents a more spherical accumulation while increasing ASP
represents considerably deviating pattern (e.g. elliptical). A more detailed description has been
given in recent studies [13, 22].
For lesion based analysis the heterogeneity of lymph-node-, bone-, liver- as well as pancre-
atic- metastases were assessed to ensure a systemic and not organ-based approach. According
to the response evaluation criteria in solid tumors (RECIST 1.1) only two lesions per organ
and not more than five per patient were included. In the case of more than two metastases per
organ ASP was derived from two individual lesions with the most representative SSR-uptakes
on visual assessment.
The association between ASP and results from RECIST-evaluation was evaluated for three
different time points (pre PRRT: mean = 4 weeks, range: 1–9 weeks), 4 months post PRRT,
and 12 months post PRRT). In generally, morphological assessment was performed by CE-CT.
Alternatively, CE-MRI was used for morphological evaluation (contrast-enhanced, CE-MRI;
n = 23/33 70%) if available. Analysis of the CE-CT (CE-MRI) data was performed using dedi-
cated radiologic workstation INFINITT (INFINITT Healthcare Co., Ltd., Seoul, South Korea).
In order to permit comparison with CE-CT, generally the short axis of lymph-nodes and long
diameters in the transverse plane for liver, pancreatic and bone metastases were drawn.
Lesions with a short axis of<15 mm (lymph nodes) and<10 mm (pancreas, liver lesions,
bone lesions) were not included into analysis to avoid partial volume effects. The morphologi-
cal changes in diameter were classified according to the RECIST 1.1 guidelines. Definition of
VOIs and calculation of the diameter were performed in consensus by two physicians. The dif-
ferent classes were further cumulated in responding lesions (RL [SD, PR, CR], n = 104) and
non-responding lesions (NRL [PD], n = 27). The rationale for this definition was published
elsewhere [23].
Statistical analysis
Data analyses were performed using SPSS 22 (IBM Corp., Armonk, NY, USA). Descriptive val-
ues were expressed as median, interquartile range (IQR, 25th percentile–75th percentile), and
range (minimum–maximum) and depicted as boxplots. According to histograms and quan-
tile-quantile plots, the distribution of data-sets was assumed non-parametric. The ASP within
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the context of intra-therapeutic dosimetry was analyzed using the Kruskal-Wallis test and
receiver operating characteristic curve (ROC). The optimal threshold for separation of RL and
NRL was calculated using the Youden’s index [24].
The cutoff values were assessed separately for prediction response at 4 and 12 months post
PRRT. ASP values was binarized using ROC cutoffs and the associated sensitivity and specific-
ity were determined. Statistical significance was assumed at at a P value < 0.05 and high signif-
icance at P value < 0.001. A subanalysis was performed in patients who underwent a
pretherapeutic [111In]octreotide SPECT/CT. The correlation of ASP[In] and ASP[Lu] was com-
pared by Spearman’s rank correlation coefficient rho (ρ) and the limits of agreement were
determined in a Bland-Altman diagram. Concordance was assumed at a deviation of� 5%.
Results
Of the 33 patients, 10/33 (30.3%) patients had a GEP-NEN including the primary tumor of the
foregut (stomach, pancreas and duodenum); in 13/33 (39.4%) patients, the primary occurred
in the midgut (jejunum, ileum, and proximal colon); in 5/33 (15.2%) patients, the tumor origin
was localized in the hindgut (the remaining two thirds of colon and rectum). 5/33 (15.2%)
patients suffered from cancer of unknown primary (CUP). All NENs were well differentiated,
low (G1) to intermediate (G2) grade. Antigen Ki-67, the proliferation index, ranged from
1–17% (median 4%). Chromogranin A (CgA) levels ranged between 94–12600 μg/l (median
632). All patients showed inoperable, metastasized NEN and had undergone different treat-
ment modalities such as surgical intervention (n = 29/33, 87.9%), somatostatin analogue ther-
apy (n = 31/33, 93.9%) or chemotherapy (n = 6/33, 18.2%). Routinely acquired patient data
and characteristics are illustrated in Table 1.
A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5)
were analyzed. Of the 131 lesions, 104 lesions had been assigned to the RLs and 27 to the NRLs







CUP-NEN (n) 5 (15.15%)





Ki-67 (%)� 6� (range, 1–17)
Cromogranin A� (μg/l) 632� (range, 94–12600)
PRRT Number of cycles 3.3� (IQR, 3–4)
Administered dose 200 mCi (7,4 GBq)
Detailed therapy and patient characteristics in systematic overview: GEP-NEN, gastro-enteropancreatic
neuroendocrine neoplasm; CUP-NEN, neuroendocrine neoplasm of unknown primary
� = median and range/ IQR, interquartile range; PRRT, peptide receptor radionuclide therapy; GBq, gigabequerel,
mCi, millicurie.
https://doi.org/10.1371/journal.pone.0216781.t001
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according to morphologic assessment [23]. There was no significant difference in the func-
tional tumor volume (FTV) between both response groups prior treatment with [177Lu]
DOTATATE-PRRT (p> 0.05).
Lesion response
Assessment of the pre-therapeutic lesion diameters revealed 19.2 mm (IQR, 13.7–33.3 mm;
range, 10.0–100.0 mm) for RL and 19.6 mm (IQR, 14.2–35.0 mm; range, 12.0–104.6 mm) for
NRL. After 4-month follow up analyses of the RLs showed a significantly decreased median
lesion size in RL of 16.9 mm (IQR, 13.0–29.5; range, 0.0–75.0; p< 0.001). Assessment of the
NRLs demonstrated a significant increase in diameter to 23.2 mm (IQR, 16.1–40.0; range,
10.0–124.6; p< 0.001). Kruskal-Wallis test depicted a highly significant difference in the diam-
eter of RLs and NRLs after two cycles, i.e. 4-months, of [177Lu]DOTATATE-PRRT (16.9 mm;
IQR, 13.0–29.5 vs. 23.2 mm; IQR, 16.1–40.0; p< 0.001).
After 12 months follow-up, the median lesion size in RLs showed a reduction in diameter
to 13.9 mm (IQR, 10.2–24.0; range, 0.0–63.0). The median lesion size in NRLs increased to
29.0 mm (IQR, 19.0–49.0; range, 15.0–136.4) after treatment. A highly significant difference
was detected in the diameter of RLs and NRLs compared at initial measurement and after
treatment (13.9 mm; IQR, 10.2–24.0 vs. 29.0 mm; IQR, 19.0–49.0; p< 0.001).
Fig 1 presents a typical example of an RL, and a representative case of an NRL.
Potential predictive relevance of ASP
Lesions with high ASP[Lu] showed a significantly poorer response to PRRT: PD, 11.3 (IQR:
8.5–15.5; range, 2.4–21.3); SD, 3.4 (IQR: 2.1–4.5; range, 0.2–18.0). PR, 1.7 (IQR: 0.9–2.8; range,
0.0–5.5). CR, 0.5 (IQR: 0.0–1.3; range, 0.0–2.8; Kruskal-Wallis, p< 0.001; Fig 2A and 2C).
Fig 1. Representative responding lesion (RL) and non-responding lesion (NRL). Baseline SPECT/CT during dosimetry (24h p.i.). Representative example of one
responding lesion in liver segment VI (A) of a 48-year-old man suffering from metastatic duodenal NEN. The lesion can be detected on SPECT (B) and is illustrated by
orange bars on CT at baseline (E) and after 12 months follow-up (F). The lesion decreased from 3.9 cm with a functional SPECT-volume of 19.7 ml to 2.3 cm after 4
cycles’ [177Lu]DOTATATE-PRRT and 12 months follow-up, respectively. Images (C,D,G,H) showing a typical example of non-responding lesions. A 59-year-old
woman suffering from pancreatic (P)-NEN with predominant liver metastases. Hepatic metastases can be detected on CT (G) as well as on SPECT (D) and image fusion,
SPECT/CT (C). The lesions’ measurements are displayed by orange bars. Two exemplary lesions in liver segment VII and VIII (G) are shown with a maximum diameter
of 3.5 cm (functional tumor volume [FTV] 26.4 ml) and 4.6 cm (FTV 34.0 ml) prior to treatment. After two cycles of [177Lu]DOTATATE-PRRT, tumor diameters
increased to 4.2 cm (segment VII) and 7.0 cm (segment VIII). As an additional finding, new metastases are highlighted with white arrow heads (H).
https://doi.org/10.1371/journal.pone.0216781.g001
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Mann-Whitney U test analysis revealed a significantly lower ASP[Lu] in RLs (2.9%; IQR,
0.9–3.9; range, 0.0–18.0) compared to NRLs (11.3%; IQR, 8.5–15.5; range, 2.4–21.3; p<0.5; Fig
2B and 2D)
Receiver Operating Characteristics (ROC) analysis revealed the highest area under the
curve (AUC) for ASP to separate between RLs and NRLs after 4 months (AUC 0.85, p<0.001).
The optimal cutoff value from ROC analysis was 6.39% (sensitivity and specificity, 77.0 and
88.0%; Fig 3). According to ROC-analysis, ASP after 12 months showed a highly significant
AUC of 0.94 (p<0.001) to differentiate between the two response groups. The optimal cutoff
for ASP was >5.45% (sensitivity and specificity, 96.0% and 82.0%, respectively; Fig 3).
Correlation of ASP[In] and ASP[Lu]
From the overall cohort of 33 patients, 20 patients, containing a pre-therapeutic [111In]octreo-
tide SPECT/CT (77 lesions; liver: n = 60, lymph nodes: n = 11, bone: n = 4, pancreas: n = 2)
Fig 2. Box plot analysis of ASP. ASP clustered by RECIST criteria after (A) 4 and (C) 12-months follow-up. B and D shows ASP for responding (RL) and non-
responding lesions (NRL) for the corresponding follow-up examinations at 4 and 12 months, respectively.
https://doi.org/10.1371/journal.pone.0216781.g002
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were analyzed in a subgroup. The optimal threshold for the pre-PRRT estimated ASP[In] was
<5.12% (sensitivity 90% and specificity 93%) and for the intra-therapeutically estimated
ASP[Lu] <5.02% (sensitivity 92% and specificity 89%). The correlation coefficient was ρ = 0.72
(p<0.01, Fig 4). The mean absolute difference between ASP[In] and ASP[Lu] was -0.04% (95%
Limits of Agreement, -6.1–6.0). 10/77 lesions (7/60 liver, 1/10 lymph nodes, 2/6 others) were
discordant (absolut difference>5%).
Discussion
In this retrospective study, we investigated the spatial heterogeneity (ASP) in SSR-positive/
functional metastatic GEP-NEN, using intra-therapeutic SPECT/CT data derived from the
first cycle PRRT. Using this methodology we showed a strong association of ASP with mor-
phological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. Even
in diagnostic and in therapeutic imaging using [111In]-OctreoScan or [177Lu]-PRRT we dem-
onstrated a strong correlation, resulting in high sensitivity and specificity.
A number of studies have already dealt with different texture analyses aimed at differentia-
tion between benign and malignant lesions [25]. The tumor heterogeneity in lung carcinoma
was evaluated by CT texture analysis. Considering a quite good contrast in lung tissue the
quantification within lung tumors can be easily assessed. However, this is not the case within
liver or other organ lesions. Here CT delination would be more challenging until semi-auto-
matic segmentation of tumor delineation is limited due to worse tissue contrast in CT images.
Lesions have to be evaluated in a manually, volumetric analysis–slice by slice. MRI delivers a
better soft tissue contrast and the potential for accurate segmentation of metastases in the liver
and other organs, respectively. Besides, several other studies worked with texture oriented
analysis of morphologic data from CT or MRI in various entities (e.g. lung carcinoma [26] or
Fig 3. ROC curve comparison—4 and 12 months follow-up. ROC for the association of ASP with morphological treatment response (measures 4 months post first
PRRT revealed an AUC = 0.85, p<0.001; A). The optimal cutoff for ASP in prediction of NRL was>6.39% (sensitivity and specificity, 77.0% and 88.0%). After 12
months (B), ASP showed an AUC of 0.94, p<0.001. The optimal cutoff for ASP was>5.45% (sensitivity and specificity, 96% and 82%).
https://doi.org/10.1371/journal.pone.0216781.g003
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colorectal cancer [27]), our analysis was based on SSR expression estimated by functional
imaging. The predictive and prognostic importance of metabolic spatial heterogeneity of
tumor lesions was also demonstrated for different cancer types e.g. using 18F-fluorodeoxyglu-
cose (FDG)-PET/CT with partly promising results [22, 28]. Corresponding observations have
also been published by Werner et al. who reported on the tumor entropy as a surrogate param-
eter assessed by [68Ga]DOTATATE- or [68Ga]DOTATOC-PET/CT in patients with late-stage
GEP-NEN prior PRRT [16].
Heterogeneity was the favored parameter in distinction between responder and non-
responder. In particular, heterogeneity parameters (such as homogeneity, correlation, size
Fig 4. Spearman’s rank correlation ASP[In] and ASP[Lu]. Scatterplot showing the correlation of ASP estimated from pre-therapeutic [
111In]-octreotide
SPECT/CT [ASP-(111)In] and intra-therapeutic ASP [ASP-(177)Lu] (ρ = 0.72, p<0.01).
https://doi.org/10.1371/journal.pone.0216781.g004
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variation and short zone emphasis and “entropy” with the highest AUC of 0.70) outperformed
conventional parameters like standardized uptake value (SUV) and total receptor expression.
In line with these findings, heterogeneity analysis of thyroid cancer showed only significant
results in a patient-based setting. Despite our results, in a lesion based analysis only the param-
eter “entropy” demonstrated with an AUC of 0.73 and a definitely lower sensitivity of 67% and
a specificity of 75% response prediction [29]. For adequate therapy-monitoring lesion-based
control is always preferable compared to patient-based follow-up. In NEN the mitotic count
(MC) and Ki-67 are the most common and reliable biomarkers for cell-proliferation and thus,
indicators for biological phenotypes [30, 31]. Although MC was used as the biomarker for
GEP-NEN during the last decades, finally Khan et al. [32] showed the disparity of MC and Ki-
67 and favored Ki-67 as a prognostic marker in grading. Actual Ki-67 plays the major role in
dividing GEP-NEN into different grades of disease (G1-3 NEN/ G3-NEC) which directly affects
therapy management [33]. Unfortunately, the Ki-67, as a prognostic marker, delivers some pit-
falls, physicians have to be aware of. Assessment of Ki-67 depends on expertise of the reporting
pathologist [34] and core biopsies represent only a small tumor sample, which impedes accu-
rate heterogeneity assessment, especially of intermediate G2-lesion [35]. Lastly, Ki-67 index is
known to fluctuate in some patients, not only with the choice of therapy but also during the
time of treatment [36, 37]. Considering these findings, non-invasive and reliable whole-body
assessment of inter-lesional heterogeneity may reflect the whole tumor burden in a more rep-
resentative way–taking the divergent tumor areas into account. Even the well-established
urine and serum-based parameters for treatment monitoring and follow-up, such as 5-hydro-
xyindole acetic acid (5-HIAA) [37] and Chromogranin A (CgA) [38], failed as prognostic bio-
marker. Since 18–33% of all patients with metastatic GEP-NEN show PD after PRRT, ASP
might deliver a reliable surrogate parameter in selecting potential non-responder [39, 40].
Especially, those patients can benefit from an early therapy-switch. Applying the ASP in pre-
therapeutic octreotide-scintigraphy, we could recently demonstrate that low ASP predicts
response to PRRT [13]. However, when dealing with elaborative predictive parameters, it is
advantageous to use comparable DOTA-conjugates, such as intra-therapeutic [177Lu-DOTA0,
Tyr3]octreotate, with equal SSR-affinity to ensure robustness of the test and to minimize
varieties.
Nevertheless, subgroup analysis presented a high correlation of ASP[In] and ASP[Lu] and
thus, validated the method. The marginal better area under the curve for ASP, obtained in pre-
therapeutic SPECT/CT imaging, might has been affected by a smaller study population bias.
More recently, functional imaging of NEN with 68Ga-labelled DOTA analogues (e.g.,
TATE/ TOC/ NOC) is the preferred SSR-imaging in follow-up examinations, due to better
sensitivity, spatial resolution and less radiation [41]. Although there is still limited data avail-
able regarding PET-based follow-up, the ENETS consensus guidelines recommend MRI/ CT
every 3–12 months and a receptor imaging in G1-2 P-NEN each 12–24 months after treatment.
If there is progression suspected, even anytime earlier [42]. Moreover, the post-therapeutic
scan is performed during therapeutic procedure (e.g. for dosimetry) immediately after treat-
ment (24 h p.i.). Providing an early surrogate for tumor response from analyzing. Our results
suggest that ASP may deliver a strong approach in intra-therapeutic risk monitoring, indicat-
ing that follow-up intervals, e.g. CT every 3–12 months, [68Ga]DOTANOC-PET/CT every 12–
24 months, can be even prolonged. An encouraging aspect is the synergistic character of the
ASP evaluation. ASP analysis uses functional data from standard diagnostics in patients with
GEP-NEN or from dosimetry (in treatment validation) providing benefits without an addi-
tional test.
Different limitations may arise: Contrary to other qualitative visual scores, the ASP may
deliver a semi-automatic parameter, which ensures reproducibility and robustness in
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prediction response. Nevertheless, the ASP is not a scanner independent surrogate parameter.
It can be hypothesized that ASP is in small lesion affected by partial volume effect. Mainly due
to remarkable progress in functional imaging and resolution, lesions smaller than 2.5ml [22],
which used to appear with symmetrical sphere shape, can be depicted these days in less than a
few millimeters in size. Thus, modern SPECT-devices, such as cadmium-zinc-telluride (CZT)
detectors, exhibit a higher spatial resolution [43]. This might avoid adulteration of the ASP in
smaller lesions. The limitations of our study are the small sample size, no comparison group
and retrospective design. Nevertheless, considering GEP-NEN are commonly rare tumor
entity [1], we were able to provide valuable findings and demonstrate significant effects that
show some support for our hypotheses. However, further validation of ASP as a potential pre-
dictive marker is still required.
Conclusion
Pre- and intra-therapeutic ASP shows a strong correlation with morphological treatment
response and might represent a potential predictive marker for PRRT. Further assessment of
its predictive value is worthwhile and might improve therapeutic decision making in NEN.
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